Cargando…

Radiation combined with immune checkpoint inhibitors for unresectable locally advanced non-small cell lung cancer: synergistic mechanisms, current state, challenges, and orientations

Until the advent of immune checkpoint inhibitors (ICIs), definitive radiotherapy (RT) concurrently with chemotherapy was recommended for unresectable, locally advanced non-small cell lung cancer (LA-NSCLC). The trimodality paradigm with consolidation ICIs following definitive concurrent chemoradioth...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wu, Leilei, Zhang, Zhenshan, Bai, Menglin, Yan, Yujie, Yu, Jinming, Xu, Yaping
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10207766/ https://www.ncbi.nlm.nih.gov/pubmed/37221584 http://dx.doi.org/10.1186/s12964-023-01139-8

Ejemplares similares

Development of EGFR TKIs and Options to Manage Resistance of Third-Generation EGFR TKI Osimertinib: Conventional Ways and Immune Checkpoint Inhibitors
por: Wu, Leilei, et al.
Publicado: (2020)

Immune Checkpoint Inhibitors for Unresectable Hepatocellular Carcinoma
por: Abd El Aziz, Mohamed A., et al.
Publicado: (2020)

Efficacy of Immune Checkpoint Inhibitors in Patients With EGFR Mutated NSCLC and Potential Risk Factors Associated With Prognosis: A Single Institution Experience
por: Bai, Menglin, et al.
Publicado: (2022)

Current evidence and future perspectives of immune-checkpoint inhibitors in unresectable malignant pleural mesothelioma
por: Hotta, Katsuyuki, et al.
Publicado: (2020)

Immune checkpoint inhibitors for unresectable or metastatic pleomorphic dermal sarcomas
por: Helbig, Doris, et al.
Publicado: (2022)

The Synergistic Effect of PARP Inhibitors and Immune Checkpoint Inhibitors
por: Wu, Zhaozhen, et al.
Publicado: (2021)

Tumor metabolic and secondary lymphoid organ metabolic markers on 18F-fludeoxyglucose positron emission tomography predict prognosis of immune checkpoint inhibitors in advanced lung cancer
por: Jin, Peng, et al.
Publicado: (2022)

Combined Stereotactic Body Radiotherapy and Checkpoint Inhibition in Unresectable Hepatocellular Carcinoma: A Potential Synergistic Treatment Strategy
por: Chiang, Chi-Leung, et al.
Publicado: (2019)

Predictors of Response and Survival in Immune Checkpoint Inhibitor-Treated Unresectable Hepatocellular Carcinoma
por: Lee, Pei-Chang, et al.
Publicado: (2020)

Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: Current Progresses and Challenges
por: Liu, Hao-Tian, et al.
Publicado: (2021)

Immune checkpoint inhibitor plus tyrosine kinase inhibitor for unresectable hepatocellular carcinoma in the real world
por: Xie, Diyang, et al.
Publicado: (2021)

Current landscape and future directions of biomarkers for predicting responses to immune checkpoint inhibitors
por: Zhu, Yingming, et al.
Publicado: (2018)

Risk of HBV reactivation in patients with immune checkpoint inhibitor-treated unresectable hepatocellular carcinoma
por: Lee, Pei-Chang, et al.
Publicado: (2020)

Cardiotoxicity associated with immune checkpoint inhibitors: Current status and future challenges
por: Gan, Lu, et al.
Publicado: (2022)

Current Trends in Glioblastoma Multiforme Treatment: Radiation Therapy and Immune Checkpoint Inhibitors
por: Nicholas, Sarah, et al.
Publicado: (2013)

Efficacy and Safety Associated With Immune Checkpoint Inhibitors in Unresectable Hepatocellular Carcinoma: A Meta-analysis
por: Jácome, Alexandre A., et al.
Publicado: (2021)

Gut microbiota and metabolites associate with outcomes of immune checkpoint inhibitor–treated unresectable hepatocellular carcinoma
por: Lee, Pei-Chang, et al.
Publicado: (2022)

Prognostic model of immune checkpoint inhibitors combined with anti-angiogenic agents in unresectable hepatocellular carcinoma
por: Li, Xiaomi, et al.
Publicado: (2022)

Oligoprogression of Solid Tumors on Immune Checkpoint Inhibitors: The Impact of Local Ablative Radiation Therapy
por: Sindhu, Kunal K., et al.
Publicado: (2022)

Neoadjuvant Multikinase Inhibitor in Patients With Locally Advanced Unresectable Thyroid Carcinoma
por: Nava, Carla Fernanda, et al.
Publicado: (2019)

Immunomodulatory role of azithromycin: Potential applications to radiation-induced lung injury
por: Yan, Yujie, et al.
Publicado: (2023)

Combination of molecularly targeted therapies and immune checkpoint inhibitors in the new era of unresectable hepatocellular carcinoma treatment
por: Liu, Ze-Long, et al.
Publicado: (2021)

Lenvatinib plus transarterial chemoembolization with or without immune checkpoint inhibitors for unresectable hepatocellular carcinoma: A review
por: Sun, Liwei, et al.
Publicado: (2022)

Unresectable hepatoblastoma: current perspectives
por: Trobaugh-Lotrario, Angela D, et al.
Publicado: (2017)

Natural killer cells and immune-checkpoint inhibitor therapy: Current knowledge and new challenges
por: Poggi, Alessandro, et al.
Publicado: (2021)

Management of Unresectable Localized Pelvic Bone Sarcomas: Current Practice and Future Perspectives
por: Soares do Brito, Joaquim, et al.
Publicado: (2022)

A narrative review of synergistic drug administration in unresectable locally advanced non-small cell lung cancer: current landscape and future prospects in the era of immunotherapy
por: Li, Shuyan, et al.
Publicado: (2020)

Transarterial Chemoembolization Combined With Immune Checkpoint Inhibitors and Tyrosine Kinase Inhibitors for Unresectable Hepatocellular Carcinoma: Efficacy and Systemic Immune Response
por: Yang, Fei, et al.
Publicado: (2022)

Current Status of Angiogenesis Inhibitors as Second-Line Treatment for Unresectable Colorectal Cancer
por: Otsu, Satoshi, et al.
Publicado: (2023)

Development and Assessment of Nomogram Based on AFP Response for Patients with Unresectable Hepatocellular Carcinoma Treated with Immune Checkpoint Inhibitors
por: Zhang, Yi, et al.
Publicado: (2023)

Current Landscape and Potential Challenges of Immune Checkpoint Inhibitors in Microsatellite Stable Metastatic Colorectal Carcinoma
por: San-Román-Gil, María, et al.
Publicado: (2023)

Synergistic Immuno Photothermal Nanotherapy (SYMPHONY) for the Treatment of Unresectable and Metastatic Cancers
por: Liu, Yang, et al.
Publicado: (2017)

Hyperthermia combined with immune checkpoint inhibitor therapy: Synergistic sensitization and clinical outcomes
por: Liu, Pengyuan, et al.
Publicado: (2022)

Dose escalation of radiation therapy with or without induction chemotherapy for unresectable locally advanced pancreatic cancer
por: Ma, Sung Jun, et al.
Publicado: (2018)

Checkpoint Inhibition in the Treatment of Unresectable, Advanced Lymphoepithelioma-like Hepatocellular Carcinoma
por: Hermel, David J., et al.
Publicado: (2021)

Immune checkpoint inhibitors in lymphoma: challenges and opportunities
por: Hatic, Haris, et al.
Publicado: (2021)

Timing of Adjuvant Chemoradiation in pT1-3N1-2 or pT4aN1 Esophageal Squamous Cell Carcinoma After R0 Esophagectomy
por: Wu, Leilei, et al.
Publicado: (2020)

Clinical efficacy of immune checkpoint inhibitors in the treatment of unresectable advanced or recurrent gastric cancer: an evidence-based review of therapies
por: Togasaki, Kazuhiro, et al.
Publicado: (2018)

Immune Checkpoint Inhibitors for the Treatment of Unresectable Stage III Non–Small Cell Lung Cancer: Emerging Mechanisms and Perspectives
por: Inoue, Hiroyuki, et al.
Publicado: (2019)

Response to Immune Checkpoint Inhibitor Therapy in Patients with Unresectable Recurrent Malignant Pleural Mesothelioma Shown by FDG-PET and CT
por: Kitajima, Kazuhiro, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_h1vvommj5ce9p8cj7a467oe55r